Abstract:Objective To evaluate the clinical efficacy and prognosis of rituximab chemotherapy in patients with mantle cell lymphoma (MCL). Methods The clinical data of 42 patients with advanced MCL admitted to the Dandong First Hospital from July 2011 to July 2021 were analyzed retrospectively. All patients were treated with rituximab. The MCL International Prognostic Index (MIPI) was used to evaluate the prognosis of the patients, the ECOG score was used to evaluate the functional status of the patients, the treatment efficacy, disease control rate (DCR), objective response rate (ORR) and incidence of adverse reactions were evaluated, and the Kaplan-Meier method was used to evaluate the progression free survival (PFS) and overall survival (OS). The clinical features, molecular pathology, treatment response and prognostic factors were analyzed by Cox regression. Results The median age of 42 patients was 70 years old, 31 males and 11 females. Twenty-seven patients received rituximab combined with CHOP chemotherapy, 6 received rituximab combined with bendamustine chemotherapy, and 9 received rituximab combined with ibrutinib chemotherapy. The objective remission rate of 42 patients with advanced MCL was 42.8%, the disease control rate was 61.9%, the median total survival time was 63 months (95%CI: 50.030~75.930), and the median progression free survival(PFS) was 18 months (95%CI: 6.645-29.355). Skin rash and interstitial pneumonia were the most common adverse events. Conclusions Treatment with rituximab for advanced MCL has a good short-term effect and tolerable side effects, the disease remission rate of rituximab combined with Bendamustine was better than that of the other two regimens.